Education
About Us
Working with TipRanks
Follow Us
Rohto Pharmaceutical Co Ltd (JP:4527)
:4527
RESEARCH TOOLSreports
Total Valuation
Rohto Pharmaceutical Co has a market cap or net worth of ¥560.66B. The enterprise value is ¥808.94B.
Market Cap¥560.66B
Enterprise Value¥808.94B
Share Statistics
Rohto Pharmaceutical Co has 236.18M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding236.18M
Owned by Insiders
Owned by Instutions
Financial Efficiency
Rohto Pharmaceutical Co’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee¥37,298,388.208
Profits Per Employee¥4,177,985.948
Employee Count7,259
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Rohto Pharmaceutical Co is ―. Rohto Pharmaceutical Co’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Rohto Pharmaceutical Co had revenue of ¥270.75B and earned ¥30.33B in profits. Earnings per share was ¥132.77.
Revenue¥270.75B
Gross Profit¥156.61B
Operating Income¥41.13B
Pretax Income¥41.18B
Net Income¥30.33B
EBITDA50.51B
Earnings Per Share (EPS)132.77
Cash Flow
In the last 12 months, operating cash flow was ¥8.59B and capital expenditures ¥0.00, giving a free cash flow of ¥8.59B billion.
Operating Cash Flow¥8.59B
Free Cash Flow¥8.59B
Free Cash Flow per Share¥36.36
Dividends & Yields
Rohto Pharmaceutical Co pays an annual dividend of ¥17.00, resulting in a dividend yield of 1.40%
Dividend Per Share¥17.00
Dividend Yield1.40%
Payout Ratio13.11%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.68
52-Week Price Change-14.10%
50-Day Moving Average2.27K
200-Day Moving Average2.94K
Relative Strength Index (RSI)58.39
Average Volume (3m)1.38M
Important Dates
Rohto Pharmaceutical Co upcoming earnings date is May 9, 2025, TBA.
Last Earnings DateFeb 12, 2025
Next Earnings DateMay 9, 2025
Ex-Dividend DateMar 28, 2025
Financial Position
Rohto Pharmaceutical Co as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Rohto Pharmaceutical Co has paid ¥10.83B in taxes.
Income Tax¥10.83B
Effective Tax Rate―
Enterprise Valuation
Rohto Pharmaceutical Co EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Rohto Pharmaceutical Co has ¥73.62B in cash and marketable securities with ¥45.87B in debt, giving a net cash position of -¥27.75B billion.
Cash & Marketable Securities¥73.62B
Total Debt¥45.87B
Net Cash-¥27.75B
Net Cash Per Share-¥117.51
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Rohto Pharmaceutical Co is ¥2697.03, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target¥2697.03
Price Target Upside13.63%
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast12.14%
EPS Growth Forecast-4.25%